Sunday, September 19, 2021
HomeMedtechMasimo Launches Single-patient-use rainbow® SuperSensor™

Masimo Launches Single-patient-use rainbow® SuperSensor™

NEUCHATEL, Switzerland– Masimo (NASDAQ: MASI) announced today the CE marking and commercial launch in Europe of the single-patient-use adhesive rainbow® SuperSensor™, compatible for use with both Masimo and third-party monitors with Masimo rainbow® technology inside. In an industry first, the comprehensive, convenient, and multi-purpose SuperSensor uses 12 LEDs to simultaneously offer 12 blood constituent parameters noninvasively and continuously: SET® oxygen saturation (SpO2), total hemoglobin, SpHb®, carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), oxygen reserve index (ORi™), PVi®, RPVi™, pulse rate (PR), respiration rate (RRp®), perfusion index (Pi), fractional oxygen saturation (SpfO2), and oxygen content (SpOC™)—all on the same single-patient-use adhesive sensor. By allowing clinicians to noninvasively and continuously monitor so many different physiologic indicators simultaneously, the SuperSensor offers the ability to assess the patient’s status continuously.

At the core of the SuperSensor is Masimo SET® pulse oximetry, which has been clinically proven to help care teams enhance patient safety and improve patient outcomes; in fact, more than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies in clinical settings and motion and low perfusion conditions, providing clinicians with increased sensitivity and specificity to make critical care decisions.1 SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns,3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce deaths due to opioid overdose, while also reducing rapid response team activations, ICU transfers, and the cost of care.4-7

Continuous hemoglobin monitoring with SpHb as part of patient blood management programs has been found to help clinicians improve outcomes in both high- and low- blood loss surgeries, such as reducing the percentage of patients receiving transfusions,8 reducing the units of red blood cells transfused per patient,9-10 reducing the time to transfusion,11 and reducing costs.12 The utility of PVi, a measure of the dynamic changes in perfusion index that occur during the respiratory cycle, as an indicator of fluid responsiveness, has been demonstrated in more than 100 independent studies.13 Use of SpHb and PVi together, as part of an integrated goal-directed therapy protocol for fluid management and blood administration, has even been shown to help clinicians reduce mortality 30 and 90 days after surgery, by 33% and 29%, respectively.14

ORi is a noninvasive and continuous trending index that extends oxygen monitoring of patients receiving supplemental oxygen. By monitoring oxygenation beyond the upper limits of conventional pulse oximetry, ORi offers the potential for advanced warning of hypoxemia, during preoxygenation and intubation procedures, and of hyperoxia, in patients receiving greater concentrations of supplemental oxygen than clinically required. For example, in a study of pediatric patients undergoing general anaesthesia with orotracheal intubation, researchers found that ORi detected impending desaturation in a median of 31.5 seconds before noticeable changes in SpO2 occurred.15 A study evaluating the ability of ORi to predict mild hypoxemia during endotracheal intubation found that the time between decrease in ORi and subsequent decrease in SpO2 “may allow preventive action,” and that a higher ORi value during preoxygenation was “independently protective against hypoxemia.”16 In another study, researchers found that monitoring adult ICU patients with ORi significantly reduced the time these critically ill patients spent with moderate hyperoxia, compared to monitoring with oxygen saturation (SpO2) alone.17

SpMet helps clinicians noninvasively and continuously monitor methemoglobin levels in the blood.18 Elevated methemoglobin levels can be caused by many drugs given in hospitals, including inhaled nitric oxide (iNO) therapy,19-20 which has been used as a potential treatment for lung complications associated with COVID-19. SpMet may be an important monitoring tool during iNO therapy.

Dr. Max Jonas, Consultant in Intensive Care Medicine and Anesthesia at University Hospitals, Southampton, UK, commented, “Critically ill patients are frequently hemodynamically unstable, with variable oxygen delivery, which may be inadequate and lead to a cumulative oxygen debt, especially with noradrenaline infusions. Clinically this makes continuous monitoring and optimization of oxygen delivery using hemoglobin, fluid responsiveness, and oxygen saturation extremely important. It is also clinically invaluable being able to recognize impaired oxygen carriage, and hence content in the blood, for instance the methemoglobinemia generated by inhaled nitric oxide therapy, which we are currently frequently using during the treatment of COVID-19 pneumonitis and also for pulmonary hypertension.”

SpCO enables quick and noninvasive monitoring of carbon monoxide levels in the blood, and may lead to the identification of elevated CO levels that might otherwise go unnoticed in front-line settings such as fire rescue and mass casualty scenarios.21,22 Studies of emergency room patients have shown that SpCO may be a valuable tool for monitoring a large number of patients for possible CO exposure.23,24 For example, in a study of emergency room patients, of 32 patients diagnosed with CO poisoning, 22 would not have been identified without SpCO monitoring.25

By making SpMet, SpCO, and SpfO2 available on the same sensor, the SuperSensor provides a more complete picture of oxygenation in the presence of potential dyshemoglobin interference. Fractional oxygen saturation (FO2Hb) provides a measure of the fraction of total hemoglobin that is currently oxygenated, as opposed to SpO2, functional oxygen saturation, which measures the fraction of hemoglobin that is oxygenated based on an estimation of the effective hemoglobin available (hemoglobin capable of being oxygenated). In healthy individuals, FO2Hb is often similar to SpO2, but when dyshemoglobin levels are elevated, FO2Hb may be more representative of the total oxygen-carrying capacity of hemoglobin than SpO2. In the presence of dyshemoglobins, SpO2 may appear “normal,” but SpfO2—a noninvasive, continuous measurement of FO2Hb—may provide more insight into a possible oxygenation impairment. Combined with the ability to monitor SpCO and SpMet on the same sensor, clinicians now have additional information to help determine if a dyshemoglobin species is responsible, and intervene appropriately.

Dr. Anne Booth, Consultant in Neuroanaethesia and PHEM at Cambridge University Hospitals, and Joint Clinical Lead – Adult Critical Care Transfers, East of England, stated, “When assessing patients’ oxygenation, we need to be prepared for the unknown, especially in Emergency and Critical Care. If there are patients that have elevated carboxyhemoglobin from prior history of smoking or from carbon monoxide exposure, their oxygen content would be impaired. Similarly, with inhaled nitric oxide therapy, which is commonly used for COVID-19, patients may be subject to high methemoglobin levels. Parameters provided on the Masimo SuperSensor, like oxygen content (SpOC) and fractional oxygen saturation (SpfO2), can help us identify the source of diminished oxygen delivery so we can react accordingly.

Dr. Aryeh Shander, Anesthesiologist and an expert in patient blood management, commented, “A key focus in our care for critically ill patients during surgery and beyond is to minimize oxygen consumption and maximize oxygen utilization. The information now available noninvasively, via a pulse oximetry-like sensor, on total hemoglobin concentration, fluid responsiveness, dyshemoglobin presence, fractional oxygen saturation, oxygen content, and more, can give us much needed and critical information to help in providing the best clinical judgements. The ultimate goal is to improve the patient’s outcome and not just treat a number.”

Dr. Kiyoyuki Miyasaka, Anesthesiologist at the National Center for Child Health and Development, Tokyo, Japan, noted, “Pulse oximetry has progressed greatly since its invention in Japan in the 1970s. With the latest sensors from Masimo, clinicians now have greater visibility of the patient’s overall oxygen delivery, helping us better understand the underlying physiology impacting their condition. I look forward to seeing how Masimo pulse oximetry can further improve patient care.”

Joe Kiani, Founder and CEO of Masimo, said, “The SuperSensor represents a key milestone in Masimo’s continued innovation journey, giving clinicians access to 12 breakthrough noninvasive measurements in a single, convenient, and comprehensive sensor as part of our RD rainbow SET® sensor family—while easing concerns about cross-contamination because of being a single-patient-use, adhesive product. I am proud of our team for delivering this innovation to the medical community.”

SpHb and SpMet monitoring are not intended to replace laboratory blood testing. Blood samples should be analyzed by laboratory instruments prior to clinical decision making. Clinical decisions regarding red blood cell transfusions should be based on the clinician’s judgment considering among other factors: patient condition, continuous SpHb monitoring, and laboratory diagnostic tests using blood samples. SpCO monitoring is not intended to be used as the sole basis for making diagnosis or treatment decisions related to suspected carbon monoxide poisoning. It is intended to be used in conjunction with additional methods of assessing clinical signs and symptoms.

The accuracy of PVi in predicting fluid responsiveness is variable and influenced by numerous patient, procedure, and device-related factors. PVi measures the variation in the plethysmography amplitude but does not provide measurements of stroke volume or cardiac output. Fluid management decisions should be based on a complete assessment of the patient’s condition and should not be based solely on PVi. In the U.S., PVi is cleared as a noninvasive, dynamic indicator of fluid responsiveness in select populations of mechanically ventilated adult patients.

Leave A Reply

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Recent Comments